As from 12 May 2020 the Journal of Virus Eradication will be published by Elsevier, a global information analytics business specializing in science and health. Now in its sixth year the journal has gone from strength to strength. In recognition and a testament to the credibility of this young journal, the impact factor is due imminently, in June this year. We feel confident that this is the right moment to hand over to Elsevier, to better ensure the further growth and success of the journal.
At a time of a global viral pandemic which we are currently experiencing, virus eradication must surely be an area of huge interest and development. Interestingly we have developed a journal which is most timely as we live through the COVID 19 pandemic. No doubt the coming months will provide plenty of submissions related to this with the hope of new therapeutics and a vaccine emerging very soon.
Thank you to all our authors, reviewers, readers, Editors: Professor Margaret Johnson and Dr Sabine Kinloch, and now joined by Dr Christina Psomas our most eminent Editorial Board and Panel.With our thanks to all our supporters
Published quarterly • Available online or through PMC • High-quality content, vigorously peer reviewed • New, improved submission system and short submission to publication times • Fast-track pathway to publish work in HIV, HBV, HCV, other viral infections including HPV, polio, herpes, flu, Ebola, Zika and coronavirus, including COVID 19 • Eminent international Editorial Board and Panel • Embracing papers on epidemiological, immunological, virological, pharmacological, preclinical, clinical and in vitro research • Open-access journal in its sixth year • Online portal for abstract supplements published in PMC • Readership comprising a growing international community
JVE is now accepted by Scopus and Clarivate Analytics to be indexed in Science Citation Expanded, JCR, Current Contents and Biological Abstracts. The Impact Factor is imminent to be announced in June 2020.